Contraception in Breast Cancer Survivors

References

1. American Cancer Society. Cancer facts and figures 2024. ACS; 2024. Accessed July 22, 2024. https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/2024-cancer-facts-figures.html
2. Cason P, Cwiak C, Edelman A, Kowal D, Marrazzo JM, Nelson AL, et al. Contraceptive technology. 22nd ed. Jones and Bartlett Learning; 2024.
3. Curtis KM, Tepper NK, Jatlaoui TC, Berry-Bibee E, Horton LG, Zapata LB, et al. U.S. medical eligibility criteria for contraceptive use, 2016. MMWR Recomm Rep 2016;65:1-103. doi: 10.15585/mmwr.rr6503a1
4. Daniels K, Abma JC. Current contraceptive status among women Aged 15-49: United States, 2017-2019. NCHS Data Brief 2020;(388):1-8.
5. Holmberg L, Iversen O, Rudenstam CM, Hammar M, Kumpulainen E, Jaskiewicz J, et al. Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. HABITS Study Group [published erratum appears in J Natl Cancer Inst 2008;100:685]. J Natl Cancer Inst 2008;100:475-82. doi: 10.1093/jnci/djn058
6. Homan GF, Davies M, Norman R. The impact of lifestyle factors on reproductive performance in the general population and those undergoing infertility treatment: a review. Hum Reprod Update 2007;13:209–23. doi: 10.1093/humupd/dml056
7. Kopeika J, Bhaduri M, Kugadas A, Reddy N, Shewbridge A, Mukherji D, et al. Planned and unplanned pregnancies in breast cancer survivors. Breast 2019;46:75-80. doi: 10.1016/j.breast.2019.05.004
8. Lambertini M, Blondeaux E, Bruzzone M, Perachino M, Anderson RA, de Azambuja E, et al. Pregnancy after breast cancer: a systematic review and meta-analysis. J Clin Oncol 2021;39:3293-305. doi: 10.1200/JCO.21.00535
9. Lambertini M, Ameye L, Hamy A, Zingarello A, Poorvu PD, Carrasco E, et al. Pregnancy after breast cancer in patients with germline BRCA mutations. J Clin Oncol 2020;38:3012-23. doi: 10.1200/JCO.19.02399
10. Lambertini M, Kroman N, Ameye L, Cordoba O, Pinto A, Benedetti G, et al. Long-term safety of pregnancy following breast cancer according to estrogen receptor status. J Natl Cancer Inst 2018;110:426-9. doi: 10.1093/jnci/djx206
11. National Comprehensive Cancer Network. Survivorship. Version 1.2024. NCCN Clinical Practice Guidelines in Oncology [after login]. NCCN; 2024. Accessed July 23, 2024. https://www.nccn.org/professionals/physician_gls/pdf/survivorship.pdf
12. Partridge AH, Niman SM, Ruggeri M, Peccatori FA, Azim HAJ, Colleoni M, et al. Interrupting endocrine therapy to attempt pregnancy after breast cancer. International Breast Cancer Study Group, POSITIVE Trial Collaborators. N Engl J Med 2023;388:1645-56. doi: 10.1056/NEJMoa2212856
13. Peccatori FA, Azim HA Jr, Orecchia R, Hoekstra HJ, Pavlidis N, Kesic V, et al. Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013;24(suppl 6):vi160-70. doi: 10.1093/annonc/mdt199
14. Poorvu PD, Gelber SI, Zheng Y, Ruddy KJ, Tamimi RM, Peppercorn J, et al. Pregnancy after breast cancer: results from a prospective cohort of young women with breast cancer. Cancer 2021;127:1021-8. doi: 10.1002/cncr.33342
15. Vaz-Luis I, Partridge AH. Exogenous reproductive hormone use in breast cancer survivors and previvors. Nat Rev Clin Oncol 2018;15:249-61. doi: 10.1038/nrclinonc.2017.207